TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02079805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Telmisartan tablets
Study: NCT00513669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEV 301& 302 in virosomes
Description: PEV 301 50 µg plus PEV 302 10 µg formulated in virosomes and injected at day 0 and 90

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inflexal V (active comparator)
Description: Inflexal V is a marketed influenza vaccine that will be given at day 0 and 90
Study: NCT01891123

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PK guided arm
Description: the dose of PTX or DOC will adjust based on the plasma drug concentration of previous cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PTX 175mg/m2, DOC 75mg/m2
Description: patients receive PTX or DOC dose based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2
Study: NCT01636882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVA21
Study: NCT04099069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anesthesia
Description: patient was insert trachial intubation or rigid bronchoscopy with ventilation under general anesthesia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: anesthesia
Description: patient was insert trachial intubation or rigid bronchoscopy with ventilation under general anesthesia
Study: NCT04546087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound scan of the cricothyroid membrane
Study: NCT04821596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biological collection
Description: Six 5 mL heparinized tubes, approximately 24 mL of blood will be collected as per standard practice. The 5 tubes collected from a given individual will be transported directly to the laboratory. In the laboratory, peripheral blood mononuclear cells (PBMC) will be prepared for the various analyses.~However, in order to minimize the effect of agents other than CoA in MS patients, it is necessary that peripheral blood mononuclear cells are collected before treatment is given: for RR MS patients treated with first-line drugs (IFNβ, glatiramer acetate, teriflunomide and dimethyl fumarate, ...), RR MS patients treated with second-line drugs (natalizumab and fingolimod, ...) and RR MS patients treated with third-line drugs (alemtuzumab, ...).
Study: NCT05034003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia crown
Description: Esthetic crowns for capping primary incisor with caries

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: composite strip crown
Description: Esthetic resin restoration for primary incisor with caries
Study: NCT02368353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive therapy
Study: NCT00428454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus-eluting stent, zotarolimus-eluting stent
Description: PCI in chronically occluded coronary artery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sirolimus-eluting stent, zotarolimus-eluting stent
Description: PCI in chronically occluded coronary artery
Study: NCT04353869

Intervention type: BIOLOGICAL
Intervention: Bio collection
Description: venous blood sampling and collection of urine

Intervention type: BIOLOGICAL
Intervention: Bio collection
Description: venous blood sampling and collection of urine

Intervention type: BIOLOGICAL
Intervention: Bio collection
Description: venous blood sampling and collection of urine
Study: NCT04082065

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: hot pack for 15 minutes Myofacial release (10 minutes) and Stretching of hamstrings and Piriformis (5 reps each with 2 second hold)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cyriax lumber manipulation group
Description: Hot Pack, Myofacial Release, stretching of hamstrings and Piriformis (five reps each with 2 seconds hold) and Cyriax Lumbar Manipulation Techniques
Study: NCT03812796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domatinostat
Description: Domatinostat is an oral tablet which will be given at a variable dose during the Phase IIA safety run in phase of the trial.~During the Phase IIB efficacy phase of the trial patients will be treated with domatinostat at the safe and tolerated combination dose identified during the Phase IIA safety run in phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a monoclonal antibody which is given via an intravenous infusion at a dose of 10mg/kg every two weeks on the first day of a two week cycle. (Day 1 q 14d) from Cycle 2 onwards.
Study: NCT01155544

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Preventing recurrence of substance use.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Intervention
Description: Preventing recurrence of substance use.
Study: NCT00604981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Description: MST is an intensive, family centered, community based treatment originally designed for use with adolescents presenting with serious mental health problems. In this study, MST interventions are aimed at increasing adolescent and family adherence to dietary and exercise recommendations and targeting barriers within the family system, and the broader community systems within which the family is embedded (peers, schools, health care). Decreasing caloric consumption consistent with recommended intake targets, increasing daily exercise and decreasing sedentary activity, are treatment focuses depending on whether the adolescent has difficulty with this aspect of weight management or not.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shapedown
Description: Shapedown, is a clinic-based, adolescent weight loss intervention. Shapedown utilizes psycho educational, behavior, and family therapy techniques in a 10-week group intervention. In order to match MST's length of intervention (6 months), three follow-up sessions are added at monthly intervals.
Study: NCT01026974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ
Study: NCT03564379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279
Description: 25 mg JNJ-42165279 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279
Description: 25 mg JNJ-42165279 tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet will be administered orally.
Study: NCT02412930

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Paravertebral Block
Description: paravertebral block was performed by ultrasound guidance at T11, T12 and L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. The injection site was covered with sterile drapes, after cleaning with 10% povidone-iodine solution.~After, patients in both groups were performed patient controlled analgesia (PCA). The PCA was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group Tramadol
Description: Patients in group T were given intravenously a loading dose of tramadol of 1 mgkg-1, 45 minutes before the end of surgery. After,patients in both groups were performed patient controlled analgesia (PCA). The PCA (CADD Legacy PCA pump, Smiths Medical MD, Inc., St. Paul, MN) was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group Tramadol
Description: Patients in group T were given intravenously a loading dose of tramadol of 1 mgkg-1, 45 minutes before the end of surgery. After,patients in both groups were performed patient controlled analgesia (PCA). The PCA (CADD Legacy PCA pump, Smiths Medical MD, Inc., St. Paul, MN) was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study: NCT01944501

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: TMS over the left temporoparietal cortex

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: TMS over the left temporoparietal cortex

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: TDCS over the left temporoparietal cortex

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: TDCS over the left temporoparietal cortex
Study: NCT01278329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garbh Sanskar audio cassette (Times Music Inc., Mumbai, India)
Description: Approximate playing time = 50 minutes. Mothers advised to listen to it once every day.
Study: NCT00769366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: humanistic-existential psychotherapy conducted in individual and group meetings

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy
Description: Optimal medical therapy after Acute myocardial infarction
Study: NCT03768219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO210
Description: APVO210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO210
Description: APVO210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO210
Description: APVO210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO210
Description: APVO210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO210
Description: APVO210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is saline based IV infusion, and is identical in appearance to active study drug.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is saline based IV infusion, and is identical in appearance to active study drug.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is saline based IV infusion, and is identical in appearance to active study drug.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is saline based IV infusion, and is identical in appearance to active study drug.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is saline based IV infusion, and is identical in appearance to active study drug.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is saline based IV infusion, and is identical in appearance to active study drug.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is saline based IV infusion, and is identical in appearance to active study drug.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is saline based IV infusion, and is identical in appearance to active study drug.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is saline based IV infusion, and is identical in appearance to active study drug.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is saline based IV infusion, and is identical in appearance to active study drug.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is saline based IV infusion, and is identical in appearance to active study drug.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is saline based IV infusion, and is identical in appearance to active study drug.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is saline based IV infusion, and is identical in appearance to active study drug.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is saline based IV infusion, and is identical in appearance to active study drug.
Study: NCT01537575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravenous immunoglobulins
Description: One course of Intravenous Immunoglobulins 0.4 g/kg/die for 5 consecutive days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Placebo
Study: NCT02864082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAT-001, 0.1%
Description: PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAT-001, 0.2%
Description: PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle for PAT-001 0.1%
Description: Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.1%.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle for PAT-001 0.2%
Description: Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.2%.
Study: NCT01281579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: Tablets, oral, 100-mg, once daily on Day 1 and on Days 4 through 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg
Description: Tablets, oral, 50-mg, once daily on Day 1 and on Days 4 through 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: Tablets, oral, 300-mg, once daily on Day 1 and on Days 4 through 9.
Study: NCT06321666

Intervention type: OTHER
Group type: OTHER
Intervention: WB-MRI
Description: All patients will undergo a CT scan (neck/thorax/abdomen/pelvis) and a WB-MRI
Study: NCT03569254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neomedlight Phototherapy Blanket
Description: The NeoMedLight® phototherapy blanket is an innovative new fiber-optic device based on LED light. Its light emitting surface area is 40.5x30 cm or 1200 cm2. The device size is 40.5 x30 cm. It incorporates fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. This device provides therapeutic light (404-515nm) to a wide extension of the body surface area. Its average irradiation footprint is 35uW / cm2 / nm ± 15%. The phototherapy was done intermittently in periods of 2 hours with 1 hour of rest for a total time of 6 hours in kangaroo position.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ohmeda-Fiber Optic Phototherapy Blanket
Description: This device is a high performance version of Ohmeda Medical's Biliblanket that uses a fiber optic cable to deliver light from a high-intensity lamp to a device composed of a fiber optic fabric. The device has a disposable liner and is left in direct contact with the patient. The patient is exposed to a light with a wavelength between 400 and 550 nanometers. The phototherapy system consists of a light emitting unit, a fiber optic cable four feet long (121.9 cm) and a lightweight mattress. It has two available sizes: 4.38 x 9.38 inches (11.12 x 23.83 cm) and 4.00 x 6.00 inches (10.16 x 15.2 cm).
Study: NCT03759873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Patient earns financial incentives (gift cards) on an escalating schedule for completing cardiac rehabilitation sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Patient earns financial incentives (gift cards) on an escalating schedule for completing cardiac rehabilitation sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management
Description: A case manager is available by phone to assist patient with attending cardiac rehabilitation sessions as well as to provide advice about cardiac symptoms and healthy behavior change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management
Description: A case manager is available by phone to assist patient with attending cardiac rehabilitation sessions as well as to provide advice about cardiac symptoms and healthy behavior change.
Study: NCT04429490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adipose tissue sampling during surgery and urine sampling
Description: Adipose tissue sampling during surgery and urine sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Adipose tissue sampling during surgery and urine sampling
Description: Adipose tissue sampling during surgery and urine sampling
Study: NCT01127178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7016 + TMZ
Description: Single-Dose PK Period (single oral dose of E7016 on Day -7) in the Dose-Escalation Component; Multiple-Dose Treatment Cycles (7 days of oral E7016 + 5 days of oral TMZ) added in Cycle 1 of the Dose-Escalation Component and in Cycles 1 through 6 of the Expansion Component.
Study: NCT02758431

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acyline
Description: Acyline 300ug/kg injection will be administered on Day 0 and on day 14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyline
Description: Acyline 300ug/kg injection will be administered on Day 0 and on day 14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyline
Description: Acyline 300ug/kg injection will be administered on Day 0 and on day 14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Placebo gel packet applied daily for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo oral tablet taken daily for 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo oral tablet taken daily for 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel
Description: Testosterone Gel applied daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel
Description: Testosterone Gel applied daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arimidex
Description: Arimidex Oral Tablet 1mg taken orally daily for 28 days
Study: NCT03370887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8601
Description: AZD8601 solution for injection, 0,5 mg/mL and 5 mg/mL will be given as 30 injections of 0.1 mg (3 mg per patient), or 1 mg (30 mg per patient) respectively on a single occasion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8601
Description: AZD8601 solution for injection, 0,5 mg/mL and 5 mg/mL will be given as 30 injections of 0.1 mg (3 mg per patient), or 1 mg (30 mg per patient) respectively on a single occasion
Study: NCT04088578

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Training
Description: Controlling movement of an object on computer screen by adjusting muscle activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Controlling movement of an object on computer screen by adjusting muscle activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation
Description: Recruits the auricular branch of the vagus nerve which activates brain structures that release chemicals mediating cortical plasticity.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sub-threshold stimulation that does not activate neural structures.
Study: NCT04670822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion
Description: The intervention group will receive multicomponent interventions consisting of 7 half-hour postnatal visits for lactation counseling, family/peer/employer support, contingent financial incentives, and early limited formula milk via syringe (optional for at-risk infants).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention placebo control
Description: The attention placebo control group will complete the same frequency and duration of study visits as the intervention group but focus on general infant care counseling and support.
Study: NCT01207128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole, micafungin
Description: Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV)Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.
Study: NCT03668028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TPX-114
Description: Subjects will be treated with autologous fibroblasts (TPX-114) during arthroscopic surgery.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Arthroscopic surgery
Description: Subjects undergo conventional arthroscopic surgery for rotator cuff repair.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Description: Subjects undergo conventional arthroscopic surgery for rotator cuff repair.
Study: NCT02262949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeStent Vascular Stent
Description: PTA followed by implantation of the LifeStent Vascular Stent (stent length 250 mm) in the SFA or popliteal artery.
Study: NCT01567371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiDCO rapid monitor
Description: Technology which provides a continuous means of monitoring various hemodynamic parameters including cardiac output and pulse pressure variability.
Study: NCT03994588

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal Mesh hernia repair
Description: The mesh will be inserted intraperitoneally for complex ventral hernia repair and fixed according the previously described ADMIR technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal Mesh hernia repair
Description: The mesh will be inserted intraperitoneally for complex ventral hernia repair and fixed according the previously described ADMIR technique.